Business Overview: Adaptive Biotechnologies Corporation (Nasdaq: ADPT)

---

Executive Summary

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company that has built a proprietary platform for reading, translating, and interpreting the immune system's genetic sequences — the T-cell and B-cell receptor repertoire. Headquartered in Seattle, Washington, Adaptive applies this platform, called immunoSEQ, to two core commercial businesses: Minimal Residual Disease (MRD) testing in blood cancers (its clonoSEQ product) and drug discovery partnerships that mine immune-repertoire data to find novel diagnostics and therapeutics.

Adaptive's core differentiator is that it has sequenced and characterized more of the human adaptive immune receptor repertoire than any other company, translating that into a commercially reimbursed diagnostic (clonoSEQ) with real, growing testing volume, alongside a pharma-partnership business (historically anchored by a large collaboration with Genentech/Roche) monetizing the same underlying dataset.

---

1. Core Business Model & How They Work

Adaptive's value chain converts immune-repertoire sequencing data into both a diagnostic product and a drug-discovery data asset:

[ Proprietary Immune Sequencing (immunoSEQ) ] ➡️ [ Massive Immune-Repertoire Database ] ➡️ [ clonoSEQ MRD Diagnostic (clinical) ] 
                                                                              ➡️ [ Pharma/Biotech Partnerships (drug discovery) ]

Key Operational Drivers

1. clonoSEQ Commercial Diagnostic: An FDA-cleared, Medicare- and increasingly commercially-reimbursed test that detects minimal residual disease in blood cancers (multiple myeloma, chronic lymphocytic leukemia, B-cell acute lymphoblastic leukemia) at far greater sensitivity than older flow-cytometry methods, driving recurring, volume-based testing revenue as oncologists adopt MRD-guided treatment decisions.
2. Immune Medicine / Pharma Partnerships: Adaptive licenses access to its immune-repertoire database and diagnostic discovery capabilities to pharmaceutical partners (most notably a long-running collaboration with Genentech, a member of the Roche Group, focused on discovering novel T-cell receptors for cancer immunotherapy).
3. Reimbursement-Driven Growth: Because clonoSEQ revenue depends heavily on payer coverage decisions (Medicare MolDx coverage, commercial payer contracts), securing and expanding reimbursement is one of Adaptive's most important commercial levers.
4. Platform Reusability: The same core immunoSEQ sequencing and bioinformatics platform underlies both the diagnostic and pharma-partnership businesses, allowing R&D investment to be leveraged across multiple revenue streams.

---

2. Business Segments

                  ┌───────────────────────────────────────────┐
                  │        Adaptive Biotechnologies             │
                  └────────────────────┬────────────────────┘
                                        │
            ┌───────────────────────────┴──────────────────────────┐
            ▼                                                       ▼
┌───────────────────────┐                             ┌───────────────────────┐
│   MRD (Diagnostics)     │                             │   Immune Medicine       │
│  (clonoSEQ - majority   │                             │  (pharma partnerships,  │
│   of revenue)           │                             │   e.g., Genentech)      │
└───────────────────────┘                             └───────────────────────┘

• MRD: clonoSEQ testing revenue, the larger and faster-growing segment, driven by expanding hematology-oncology adoption and reimbursement coverage.
• Immune Medicine: Collaboration and licensing revenue from pharmaceutical partners using Adaptive's immune-repertoire data and receptor-discovery capabilities to develop new therapeutics and diagnostics.

---

3. Competitive Landscape

                     Broad Oncology Diagnostics Platforms  <——————————————————>  Immune-Repertoire-Specific Platforms
                              │                                                        │
   Liquid biopsy/genomic       │  Guardant Health, Natera (Signatera), Foundation      │
   MRD competitors             │  Medicine                                             │
                              │                                                        │
   Immune-sequencing            │                                                        │  Adaptive Biotechnologies
   specialists                  │                                                        │  (clonoSEQ, immunoSEQ)

Competitors by Domain

Minimal Residual Disease / Liquid Biopsy Diagnostics

• Key Competitors: Natera (Signatera, primarily solid tumors but expanding), Guardant Health, and other next-generation-sequencing-based liquid biopsy companies moving into hematologic malignancy MRD testing.
• Dynamics: clonoSEQ's advantage in blood cancers is its origin in immune-receptor sequencing (highly relevant because the cancer clone itself is a lymphocyte), giving it a validated, FDA-cleared, and specifically reimbursed position in multiple myeloma, CLL, and ALL that ctDNA-based platforms (built for solid tumors) do not directly replicate.

Immune Repertoire / T-Cell Receptor Discovery

• Key Competitors: Various smaller immune-profiling and TCR-discovery companies, and in-house discovery efforts at large pharmaceutical companies.
• Dynamics: Adaptive's scale of sequenced immune repertoires (built over more than a decade) is difficult to replicate quickly, giving it a partnership-of-choice position with large pharma for immune-receptor-based drug discovery.

---

4. Strategic Strengths & Moats vs. Strategic Risks

Competitive Strengths (The Moat)

• Proprietary sequencing and bioinformatics IP: Patents and trade secrets around immunoSEQ chemistry and analysis pipelines protect Adaptive's core technology.
• Regulatory and reimbursement head start: clonoSEQ's FDA clearances and established Medicare/commercial reimbursement pathway represent years of regulatory investment that a new entrant would need to replicate from scratch.
• Proprietary data scale: Adaptive's immune-repertoire database, built from millions of sequenced samples, is a genuine data-network asset that compounds in value as it grows and improves discovery/diagnostic accuracy.
• Switching costs in oncology workflow: Once oncologists integrate clonoSEQ into a treatment-monitoring protocol for a patient, there is clinical and workflow inertia against switching tests mid-course.

Strategic Risks & Vulnerabilities

1. Reimbursement dependency: A large share of near-term revenue growth depends on continued and expanding payer coverage decisions outside Adaptive's direct control.
   • Mitigation Strategy: Ongoing clinical evidence generation (peer-reviewed publications, guideline inclusion) to support payer coverage expansion.
2. Partnership concentration in Immune Medicine: The pharma-partnership business has historically depended heavily on a small number of large collaborations.
   • Mitigation Strategy: Pursuing additional pharma partnerships and licensing deals to diversify the Immune Medicine revenue base.
3. Path to sustained profitability: Like many platform diagnostics companies, Adaptive has invested heavily in R&D and commercial buildout, requiring continued revenue scale-up to reach durable profitability.
   • Mitigation Strategy: Prioritizing clonoSEQ volume growth (the higher-margin, faster-scaling segment) as the primary path to operating leverage.

---

5. Financial Overview & Performance Matrix

---

6. Summary Conclusion

Adaptive Biotechnologies has converted a genuinely differentiated immune-sequencing platform into a real, reimbursed diagnostic business in clonoSEQ, giving it a defensible position in blood-cancer MRD testing that pure liquid-biopsy competitors built for solid tumors do not directly replicate. The parallel Immune Medicine partnership business monetizes the same underlying data asset with large pharmaceutical partners.

The central long-term question is whether Adaptive can keep expanding clonoSEQ reimbursement and adoption fast enough to reach sustained profitability, while diversifying its Immune Medicine partnership base beyond a small number of large collaborations, in a diagnostics landscape where much larger liquid-biopsy competitors are also pushing into adjacent minimal-residual-disease use cases.